Overview
Agenda
View Archive

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Evolving Immuno-Oncology Strategies in Stage III NSCLC: A Focus on Recent Evidence and Key Next Steps in Trials

Evolving Immuno-Oncology Strategies in Stage III NSCLC: A Focus on Recent Evidence and Key Next Steps in Trials


Thursday, August 19, 2021

Live, Interactive Webcast!

7:00 PM – 9:00 PM EDT

Overview

The introduction of immunotherapy into the standard of care for unresectable stage III non-small cell lung cancer (NSCLC) has led to substantial improvements in patient outcomes, which, in turn, have spurred research into methods for optimizing patient and therapy selection and therapy timing.
 
In this live, online symposium, experts in the management of NSCLC will discuss up-to-date findings and recommendations for the treatment of locally advanced, unresectable disease and emerging principles for the use of immunotherapy in these patients. These evidence-based presentations will be supplemented with case discussions to help participants contextualize and apply recent data in their practice.

Benefits of Attending

  • Hear from lung cancer experts on how to use immunotherapy in locally advanced NSCLC
  • Find out how you should be using biomarkers to select immunotherapy for stage III disease
  • Discover what the future holds for concurrent immunotherapy and definitive therapy
  • Optimize management of treatment-related toxicities in stage III NSCLC

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Target Audience

This educational program is directed toward medical, surgical, and radiation oncologists and cancer researchers. Other health care professionals involved in the study or treatment of lung cancer are also invited to participate.

Hot Topics

  • Consolidation immunotherapy for stage III NSCLC
  • Concurrent immunotherapy and chemoradiotherapy in stage III NSCLC
  • Biomarkers of response to immunotherapy
  • Coordination of multidisciplinary care for patients with locally advanced NSCLC

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the biology of tumor immunology and the scientific rationale for immune checkpoint inhibition in the management of stage III NSCLC
  • Integrate clinical trial evidence to optimize the use of immune checkpoint inhibitors in the treatment of patients with stage III NSCLC and describe ongoing studies investigating novel uses of immuno-oncology strategies
  • Evaluate biomarkers for therapeutic selection in patients with NSCLC
  • Discuss approaches to mitigate and manage the impact of immune-related adverse events in patients with NSCLC who receive immune checkpoint inhibitors

Chair

Karen L. Reckamp, MD, MS
Karen L. Reckamp, MD, MS
Director, Division of Medical Oncology
Associate Director, Clinical Research
Clinical Professor, Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center & David Geffen School of Medicine at UCLA
Los Angeles, CA

Faculty

Joel Neal, MD, PhD
Joel Neal, MD, PhD
Associate Professor of Medicine, Division of Oncology
Medical Director, Cancer Clinical Trials Office, Stanford Cancer Institute
Medical Director of Informatics, Stanford Cancer Center
Stanford, California


 
Jonathan Riess, MD, MS
Jonathan Riess, MD, MS
Associate Professor
Hematology/Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA


 
Christine A. Ciunci, MD, MSCE
Christine A. Ciunci, MD, MSCE
Associate Professor of Clinical Medicine
Abramson Cancer Center
Division of Hematology Oncology
Penn Presbyterian Medical Center
Hospital of the University of Pennsylvania
Philadelphia, PA

Registration

2 Ways to Register

  1. Online: click here.

  2. Phone: Please call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
 
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

Meeting information is accurate at the time of posting.




Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By